CELLECT BIOTECH/S’s (APOP) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of CELLECT BIOTECH/S (NASDAQ:APOP) in a research note published on Tuesday morning. They currently have a $14.00 price objective on the stock.

“We continue to expect that this cushion should be sufficient to fund operations through 2019. The January 2018 financing included unregistered warrants with an exercise price of $12.00 per ADS, which could if exercised in full accrue an additional $3.2M to the company. Assuming Cellect remains capital- efficient and warrant exercises proceed as projected, we believe the company could continue to operate well into 2020 without requiring further capital to be raised. R&D expenses were slightly below our projection at $0.8M vs. $1M, while G&A spending was somewhat above our estimate at roughly $1M vs. $0.9M. The company recorded a net loss of only $0.16 per share vs. our projection of $0.30 per share, primarily due to the favorable impact of about $0.8M in financial non- cash items.”,” HC Wainwright’s analyst wrote.

Separately, Zacks Investment Research cut CELLECT BIOTECH/S from a buy rating to a hold rating in a research report on Thursday, March 22nd.

CELLECT BIOTECH/S opened at $7.40 on Tuesday, Marketbeat.com reports. The company has a market capitalization of $38.68 million, a PE ratio of -5.07 and a beta of 4.61. CELLECT BIOTECH/S has a 12 month low of $6.12 and a 12 month high of $13.50.

CELLECT BIOTECH/S (NASDAQ:APOP) last posted its quarterly earnings data on Thursday, May 17th. The company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.14. sell-side analysts anticipate that CELLECT BIOTECH/S will post -1.3 EPS for the current fiscal year.

A hedge fund recently bought a new stake in CELLECT BIOTECH/S stock. Sabby Management LLC purchased a new position in shares of CELLECT BIOTECH/S (NASDAQ:APOP) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 243,980 shares of the company’s stock, valued at approximately $1,557,000. CELLECT BIOTECH/S makes up 0.2% of Sabby Management LLC’s investment portfolio, making the stock its 23rd biggest position. Sabby Management LLC owned approximately 4.48% of CELLECT BIOTECH/S as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 6.22% of the company’s stock.


Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply